Dacomitinib

CAS: 1110813-31-4

Ref. TR-D101575

Produktinformation

• Name: Dacomitinib
• Synonyme: 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-methoxy-6-quinazolinyl]-4-(1-piperidinyl)-, (2E)-, (2E)-N-[4-[(3-Chloro-4-fluorophenyl)amino]-7-methoxy-6-quinazolinyl]-4-(1-piperidinyl)-2-butenamide, PF 00299804, PF 299, PF 299804, (2E)-N-(4-((3-Chloro-4-Fluorophenyl)Amino)-7-Methoxy-6-Quinazolinyl)-4-(1-Piperidinyl)-2-Butenamide, (E)-N-(4-((3-chloro-4-fluorophenyl)amino)-7-Methoxyquinazolin-6-yl)-4-(piperidin-1-yl)but-2-enamide, 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-methoxy-6-quinazolinyl]-4-(1-piperidinyl)-, (2E)-, Pf 00299804, Pf 299804, Pf-00299804-03, Pf-299, Pf299804

Beschreibung

Applications Dacomitinib is an Erb-inhibitor, or an inhibitor of the members of the epidermal growth factor receptor family. Used as an ant-cancer agent due to observation of over-expressed epidermal growth factor receptor in nearly all cases of squamous cell carcinoma in the head and neck.
References Williams, J. et al.: PLoS., 9, e98557 (2014); Peters, S. et al.: Canc. Treatment Rev., 40, 917 (2014);

• Marke: TRC

Chemische Eigenschaften

• Molekulargewicht: 469.94
• Formel: C₂₄H₂₅ClFN₅O₂
• Farbe/Form: Neat
• InChl: InChI=1S/C24H25ClFN5O2/c1-33-22-14-20-17(24(28-15-27-20)29-16-7-8-19(26)18(25)12-16)13-21(22)30-23(32)6-5-11-31-9-3-2-4-10-31/h5-8,12-15H,2-4,9-11H2,1H3,(H,30,32)(H,27,28,29)/b6-5+
• InChI Key: InChIKey=ATVQZEZXTPHWTH-WTYVYLTKSA-N
• SMILES: CCCCCCCC1(CC[C@H]2[C@@H](O)CC3OC(=O)C[C@H]32)OCCO1